Rajan et al. conducted a phase 2 study of cixutumumab, which is an IGF-1R monoclonal antibody, in patients with advanced thymomas and thymic carcinomas who had previously received platinum-containing chemotherapy and reported an ORR of 14% in 37 patients with thymoma, with a DCR of 89% [29]. This evidence concerns the gene IGF1R and thymoma.